PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.34%
Net income growth above 1.5x AGEN's 4.91%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-12.79%
Both reduce yoy D&A, with AGEN at -4.00%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
35.67%
Lower deferred tax growth vs. AGEN's 249.43%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-6.19%
Negative yoy SBC while AGEN is 173.40%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
947.27%
Slight usage while AGEN is negative at -12.46%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
844.13%
A yoy AP increase while AGEN is negative at -71.30%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-18.50%
Negative yoy usage while AGEN is 46.45%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-6.19%
Both negative yoy, with AGEN at -82.33%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
46.02%
Operating cash flow growth above 1.5x AGEN's 1.07%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
81.40%
CapEx growth well above AGEN's 21.51%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.69%
Both yoy lines negative, with AGEN at -50.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
80.57%
We have mild expansions while AGEN is negative at -53.03%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-99.82%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.